LMR Partners LLP purchased a new position in BioPlus Acquisition Corp. (NASDAQ:BIOSU – Get Rating) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 250,000 shares of the company’s stock, valued at approximately $2,500,000.
A number of other hedge funds and other institutional investors have also modified their holdings of BIOSU. Condor Capital Management bought a new position in BioPlus Acquisition in the 4th quarter worth approximately $32,000. Robinson Capital Management LLC acquired a new stake in shares of BioPlus Acquisition during the 4th quarter worth approximately $163,000. Parallax Volatility Advisers L.P. acquired a new stake in shares of BioPlus Acquisition during the 4th quarter worth approximately $230,000. Landscape Capital Management L.L.C. acquired a new stake in shares of BioPlus Acquisition during the 4th quarter worth approximately $257,000. Finally, Sage Mountain Advisors LLC acquired a new stake in shares of BioPlus Acquisition during the 4th quarter worth approximately $621,000.
Shares of NASDAQ:BIOSU opened at $9.94 on Friday. BioPlus Acquisition Corp. has a 1-year low of $9.92 and a 1-year high of $10.07. The stock’s 50 day moving average price is $10.00.
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
- Get a free copy of the StockNews.com research report on BioPlus Acquisition (BIOSU)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for BioPlus Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPlus Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.